# A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab

> **NCT00001805** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 20 (—)

## Conditions studied

- Breast Neoplasms
- Colonic Neoplasms
- Lung Neoplasms
- Pancreatic Neoplasms
- Stomach Neoplasms

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00001805
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-03
- **Primary completion:** —
- **Final completion:** 2000-06
- **Target enrollment:** 20 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001805, "A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00001805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*